We tested the immunogenicity of our vaccine in vivo and demonstrated mechanistic improvement by the addition of IL-7 in modified B16 tumor models that are otherwise resistant to immunotherapy, including a uniform cure rate with PD-1+vaccine combinations in a model with limited capability for antigen loss. Here, IL7 is linked to neoplasm.